Pediatric Data Submissions: FDA Tips For Navigating Committee Review

Drug sponsors need to be pro-active and thorough in justifying their approach to pediatric studies in light of the added layer of review now conducted by the internal FDA Pediatric Review Committee, FDA's Lisa Mathis advised at the DIA annual meeting in Boston June 25